CRDL.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	69 572.00
Średni wolumen	155 880
Kapitalizacja rynkowa	187.06M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $-0.130 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.23
ATR14	$0.0100 (0.37%)

Wolumen Korelacja

Długi: 0.27 (neutral)

Krótki: 0.29 (neutral)

Signal:(43.832) Neutral

CARDIOL THERAPEUTICS INC Korelacja

10 Najbardziej pozytywne korelacje
AAX.V	0.802
ORL.TO	0.802

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CARDIOL THERAPEUTICS INC Korelacja - Waluta/Towar

-0.30
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.22
( neutral )

CARDIOL THERAPEUTICS INC Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2023
Przychody:	$0
Zysk brutto:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2022
Przychody:	$0
Zysk brutto:	$-219 908 (0.00 %)
EPS:	$-0.180

FY	2021
Przychody:	$78 760.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

CARDIOL THERAPEUTICS INC

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.